Help Lines 954-785-1121
 


You are not logged in. Upgrade Here
 <<<Previous Mid Day Report     Next Mid Day Report >>> 
 <<<Previous After Market Report Next After Market Report >>> 
You are not logged in.
This means you CAN ONLY VIEW reports that were published prior to Monday, February 19, 2024.
You MUST UPGRADE YOUR MEMBERSHIP if you want to see any current reports.

 MIDDAY BREAKOUTS REPORT - MONDAY, MARCH 16TH, 2020
Previous Mid Day Report Next Mid Day Report >>>

DOW 21309.82 -1875.8 (-8.09%) | NASDAQ 7290.13 -584.75 (-7.43%) | S&P 500 2515.45 -195.57 (-7.21%)
Time of Screening : 3/16/2020 12:33:18 PM         Report Released : 3/16/2020 12:50:05 PM
Price is: Above 52W High and Less Than 52W High but within 15% of the 52 Week High
Volume Is: At least 57.5% of 50 Day Average at the time of the screening.
More details about this report...

To View Current Notes and Data on currently Featured Stocks go to the latest
Featured Stocks Page


NONE OF OUR FEATURED STOCKS MET TODAY'S SCREENING CRITERIA FOR VOLUME AND PRICE ACTION.


Symbol - Exchange - Industry Group
Company Name
Last Chg Day
High
52 WK Hi % From Hi Volume
% DAV
DAV
ACIA - NASDAQ - Telecom-Fiber Optics
Acacia Communications
$65.00 -1.99
-2.97%
$65.62 $69.00 -5.80% 406,234
85.88%
473,000
Most Recent Note for ACIA - 3/16/2020 12:33:46 PM
Testing its 200 DMA line. Reported Dec '19 quarterly earnings +17% on +20% sales revenues. Consolidating since 7/09/19 M&A news with Cisco Systems (CSCO). Reported strong Sep and Jun '19 quarterly results after noted in the prior mid-day reports - "Earnings rose +270% on +44% sales revenues for the Mar '19 quarter, its 2nd strong quarterly comparison. Prior 5 quarterly comparisons showed shrinking sales and earnings versus the year ago periods. Went through a deep consolidation since noted with caution after it proposed a new Public Offering on 9/26/16, up from its $23 IPO on 5/13/16,"
View all notes | Alert me of new notes | Company Profile | SEC  | News | ChartC A N S L I M  
AGN - NYSE - DRUGS - Drug Manufacturers - Other
Allergan Inc
$172.00 -11.85
-6.45%
$175.99 $202.22 -14.94% 2,692,550
82.47%
3,265,000
Most Recent Note for AGN - 3/16/2020 12:34:10 PM
Gapped down today undercutting its 200 DMA line. Reported earnings +22% on +7% sales revenues for the Dec '19 quarter. Prior quarterly earnings comparisons were well below the +25% minimum guideline (C criteria). After a downturn in FY '14 earnings its growth has been steady.
View all notes | Alert me of new notes | Company Profile | SEC  | News | ChartC A N S L I M  
AMT - NYSE - TELECOMMUNICATIONS - Diversified Communication Serv
American Tower Reit
$226.44 -12.55
-5.25%
$229.81 $258.62 -12.44% 1,416,427
68.96%
2,054,000
Most Recent Note for AMT - 3/16/2020 12:34:47 PM
This REIT deeply undercut its 200 DMA line ($222) again today then rebounded above it. While perched at an all-time high the 2/11/20 mid-day report cautioned members - "Prior comparisons were well below the +25% minimum guideline (C criteria). Its annual earnings (A criteria) history has been strong."
View all notes | Alert me of new notes | Company Profile | SEC  | News | ChartC A N S L I M  
DOCU - NASDAQ - Computer Sftwr-Enterprse
Docusign Inc
$82.59 +5.27
6.82%
$85.75 $92.55 -10.76% 3,364,266
159.75%
2,106,000
Most Recent Note for DOCU - 3/16/2020 12:37:46 PM
Rebounding above its 50 DMA line ($80) after finding support at its 200 DMA line ($64). Earnings history included a -67% comparison in the Jul '19 quarter versus the year ago period, but otherwise results have been strong.

View all notes | Alert me of new notes | Company Profile | SEC  | News | ChartC A N S L I M  
EBS - NYSE - DRUGS - Biotechnology
Emergent Biosolutions
$63.84 -4.92
-7.16%
$67.57 $71.19 -10.32% 433,833
106.86%
406,000
Most Recent Note for EBS - 3/16/2020 12:39:34 PM
Recent gains have been challenging its all-time high. Reported earnings +101% on +33% sales revenues for the Dec '19 quarter, its 2nd strong quarterly comparison versus the year ago period. Fundamental concerns remain. Noted in prior mid-day reports - "Prior quarterly and annual earnings history (C and A criteria) is not a match with the fact-based investment system's guidelines."
View all notes | Alert me of new notes | Company Profile | SEC  | News | ChartC A N S L I M  
LLY - NYSE - Medical-Diversified
Lilly Eli & Co
$134.97 -4.40
-3.16%
$138.68 $147.87 -8.72% 2,666,721
61.40%
4,343,000
Most Recent Note for LLY - 3/16/2020 12:40:14 PM
Reported Dec '19 quarterly earnings +31% on +8% sales revenues, but prior quarterly comparisons were below the +25% minimum earnings guideline (C criteria) versus the year ago periods. Annual earnings (A criteria) improved steadily since a downturn in FY '14.
View all notes | Alert me of new notes | Company Profile | SEC  | News | ChartC A N S L I M  
PG - NYSE - CONSUMER NON-DURABLES - Cleaning Products
Procter & Gamble
$111.90 -2.17
-1.90%
$115.95 $128.09 -12.64% 6,466,532
74.10%
8,727,000
Most Recent Note for PG - 3/16/2020 12:42:03 PM
Earnings history is not a match with the fact-based investment system's fundamental guidelines. Slumped below 200 DMA line and recent sessions have been marked by wider than usual intra-day price swings indicative of great uncertainty.
View all notes | Alert me of new notes | Company Profile | SEC  | News | ChartC A N S L I M  
QDEL - NASDAQ - DRUGS - Diagnostic Substances
Quidel Corp
$80.86 +1.69
2.13%
$85.00 $91.73 -11.85% 229,551
78.88%
291,000
Most Recent Note for QDEL - 3/16/2020 12:44:40 PM
Perched near its all-time high. Reported earnings +23% on +15% sales revenues for the Dec '19 quarter. Prior quarterly and annual earnings (A criteria) history has been up and down, not a match with the fact-based system's fundamental guidelines.
View all notes | Alert me of new notes | Company Profile | SEC  | News | ChartC A N S L I M  
REGN - NASDAQ - DRUGS - Biotechnology
Regeneron Pharmaceutical
$461.79 -3.76
-0.81%
$484.58 $500.00 -7.64% 753,314
67.62%
1,114,000
Most Recent Note for REGN - 3/16/2020 12:47:13 PM
Perched near its 52-week high. Held its ground stubbornly following volume-driven gains. Prior mid-day reports noted - "Reported earnings +10% on +13% sales revenues for the Dec '19 quarter, and prior quarterly comparisons were below the +25% minimum earnings guideline (C criteria). Downturn in FY '15 earnings was a noted flaw in its annual earnings (A criteria) history."
View all notes | Alert me of new notes | Company Profile | SEC  | News | ChartC A N S L I M  
XEL - NYSE - UTILITIES - Electric Utilities
Xcel Energy Inc
$63.50 -3.34
-5.00%
$67.00 $72.14 -11.98% 2,654,166
70.57%
3,761,000
Most Recent Note for XEL - 3/16/2020 12:49:32 PM
Fundamental concerns remain due to sub par sales revenues and earnings history. Following a quick rebound near its 52-week high it is sputtering again near its 200 DMA line ($63).
View all notes | Alert me of new notes | Company Profile | SEC  | News | ChartC A N S L I M  
ZM - NASDAQ - Computer Sftwr-Enterprse
Zoom Video Comm Cl A
$116.23 +8.76
8.15%
$118.20 $129.83 -10.47% 9,715,212
145.02%
6,699,000
Most Recent Note for ZM - 3/16/2020 12:50:00 PM
Reported earnings +275% on +78% sales revenues for the Jan '20 quarter. Still perched near its all-time high and prior mid-day reports repeatedly noted - "Trading in a wider intra-day range has been noted as an indication of uncertainty after an impressive spurt of volume-driven gains. Rebounded following a deep consolidation. Completed its $36.00 IPO on 4/18/19. Limited annual history (A criteria) is a concern. Quarterly comparisons through Oct '19 showed very strong sales revenues and great earnings increases versus the year ago periods."
View all notes | Alert me of new notes | Company Profile | SEC  | News | ChartC A N S L I M  

THESE ARE NOT BUY RECOMMENDATIONS!  Comments contained in the body of this report are technical opinions only. The material herein has been obtained from sources believed to be reliable and accurate, however, its accuracy and completeness cannot be guaranteed. We are not an investment advisor, hence it does not endorse or recommend any securities or other investments. Any recommendation contained in this report may not be suitable for all investors and it is not to be deemed an offer or solicitation on our part with respect to the purchase or sale of any securities. All trademarks, service marks and trade names appearing in this report are the property of their respective owners, and are likewise used for identification purposes only.

This report is a service available only to active Paid Premium Members. You may opt-out of receiving report notifications at any time.  Questions or comments may be submitted by writing to FactBasedInvesting.com c/o Premium Member Services 665 S.E. 10 Street, Suite 201 Deerfield Beach, FL 33441-5634 or by calling 954-785-1121.

 We appreciate any feedback members may wish to send via the inquiry form here.

Kenneth J. Gruneisen founded Gruneisen Growth Corp. (2003), which prior to May 11, 2015, operated CANSLIM.net and CANSLIM.com both under license from Data Analysis Inc. / Investor's Business Daily. Kenneth has passed the CAN SLIM® Master's Exam. Gruneisen Growth Corp. now continues over two decades of fact based market analysis via FactBasedInvesting.com.

Copyright © 1996-2024 Gruneisen Growth Corp. All rights reserved. Protected by the copyright laws of the United States and Canada and by international treaties

Privacy Policy | Terms of Use | Contact Us